Human PD-L1 Protein (C-His) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.
Human PD-L1 Protein (C-His) final product is analyzed on Size-exclusion Chromatography. The purity of this protein is greater than 95%.
Cat #
Size
Price
Quantity
800601
25 ug
$145
800602
100 ug
$295
Product Details
Application
ELISA, BLI
Format
Liquid, Purified
Expression Host
HEK293
Target Name
PD-L1, CD274, B7-H1, PDCD1L1, PDCD1LG1,
Species
Human
Sources
Recombinant Human PD-L1 (Phe19-Thr239) with C-terminus His tag is expressed in HEK293 cell.
accession number
Q9NZQ7
Molecular Weight
The protein has a predicted molecular weight of 28 kDa and migrates at approximately 35 kDa on SDS-PAGE under DTT-reducing conditions.
Affinity Tag
C-His
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
Programmed death-ligand 1 (PD-L1, also known as CD274 or B7-H1) is a type I transmembrane glycoprotein and a key immune checkpoint molecule in the B7 family. It is broadly expressed on immune cells (such as T cells, B cells, macrophages, and dendritic cells) and in various tissues, as well as on many tumor types. PD-L1 interacts with its receptor PD-1, expressed on activated T and B cells, to deliver inhibitory signals that suppress T cell proliferation, cytokine production, and cytolytic function. This interaction plays a critical role in maintaining immune homeostasis, preventing autoimmunity, and enabling immune evasion by tumors. Therapeutic antibodies targeting PD-L1 or PD-1 have shown significant clinical benefit in cancer immunotherapy by restoring T cell activity. PD-L1 is also implicated in tolerance during pregnancy, chronic infections, and transplantation. It contains two extracellular Ig-like domains, and its expression can be induced by inflammatory cytokines such as IFN-γ.
Human PD-L1 Protein (C-His) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.
Human PD-L1 Protein (C-His) final product is analyzed on Size-exclusion Chromatography. The purity of this protein is greater than 95%.
